Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | TYMS | P04818 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8308277 | 0.89 | MEN1 (0.51) | MEN1MAPK1KMT2ANPSR1HSD17B1 | |
| SCHEMBL7624438 | 0.89 | PBRM1 (0.44) | PBRM1CASP1CASP7HSD17B10MEN1 | |
| SCHEMBL7937906 | 0.81 | MEN1 (0.40) | PBRM1CASP1CASP7HSD17B10MEN1 | |
| SCHEMBL6915238 | 0.78 | MEN1 (0.51) | MEN1MAPK1KMT2ANPSR1HSD17B1 | |
| SCHEMBL8809982 | 0.75 | HIF1A (0.41) | PBRM1HIF1AEPAS1 | |
| SCHEMBL19290149 | 0.74 | RARA (0.33) | — | |
| SCHEMBL12758100 | 0.72 | CLK4 (0.45) | HSD17B10GRM5 | |
| SCHEMBL12758097 | 0.71 | PPOX (0.39) | MEN1MAPK1KMT2ANPSR1MAOB | |
| SCHEMBL22982478 | 0.71 | MEN1 (0.56) | PBRM1CASP1CASP7HSD17B10MEN1 | |
| SCHEMBL29661202 | 0.71 | MEN1 (0.56) | PBRM1CASP1CASP7HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3121187-B1 | METALLOCENE COMPLEX AND METHOD FOR MANUFACTURING OLEFIN POLYMER | JAPAN POLYPROPYLENE CORP (JP) | 2018-10-10 | — | — | EP | disclosed |
| US-9963522-B2 | Metallocene complex and method for producing olefin polymer | JAPAN POLYPROPYLENE CORPORATION (JP) | 2018-05-08 | — | — | US | disclosed |
| US-20170081431-A1 | METALLOCENE COMPLEX AND METHOD FOR PRODUCING OLEFIN POLYMER | JAPAN POLYPROPYLENE CORPORATION (JP) | 2017-03-23 | — | — | US | disclosed |
| EP-3121187-A1 | METALLOCENE COMPLEX AND METHOD FOR MANUFACTURING OLEFIN POLYMER | Japan Polypropylene Corporation (JP) | 2017-01-25 | — | — | EP | disclosed |
| EP-0933350-A1 | Tricyclic retinoids, methods for their production and use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0933351-A1 | Tricyclic retinoids, methods for their production and use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-08-04 | — | — | EP | disclosed |
| US-5770382-A | RETINOIC ACID AND RETINOID X RECEPTOR AGONISTS; TREATINGSKIN, EYE, BRAIN, AND CARDIOVASCULAR DISORDERS; CANCER | LIGAND PHARMACEUTICALS, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| US-5770378-A | A VITAMINE A METABOLITE, POTENT DRUGS TREATING SKIN DISEASES, CANCER, EYE DISEASES, CARDIOVASCULAR DISORDERS | LIGAND PHARMACEUTICALS, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| US-5770383-A | ACTIVATE RETINOID RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| EP-0800504-A1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996020914-A1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081431-A1 | METALLOCENE COMPLEX AND METHOD FOR PRODUCING OLEFIN POLYMER | PPOX, ALOX12, PORCN | PBRM1 648/4885CASP1 2507/4885CASP7 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.